The policy that allows companies to receive tax advantages for developing drugs designed to treat rare diseases is:

The policy that allows companies to receive tax advantages for developing drugs designed to treat rare diseases is:

• A. Switching Policy
• B. Fast Track Policy
• C. OTC Policy
• D. Orphan Drug Law

Answer: (D)

Incentives for rare-disease drug development are provided by a policy that aims to encourage companies to invest in treatments for small patient populations. It offers financial and regulatory benefits to offset the high costs and limited market size. A key part of this is tax advantages for the costs associated with developing and testing these drugs, along with other supports like grant funding and a period of market exclusivity after approval. Rare diseases often struggle to attract research funding because of limited patient pools, so these incentives help make the development economically viable. The other policies don’t focus on rare-disease drug development or tax-based encouragements: switching policy isn’t a recognized framework for this purpose, fast track speeds up review without providing tax benefits, and OTC policy deals with over-the-counter status rather than development incentives. Therefore, the policy described is the Orphan Drug Law.

Incentives for rare-disease drug development are provided by a policy that aims to encourage companies to invest in treatments for small patient populations. It offers financial and regulatory benefits to offset the high costs and limited market size. A key part of this is tax advantages for the costs associated with developing and testing these drugs, along with other supports like grant funding and a period of market exclusivity after approval. Rare diseases often struggle to attract research funding because of limited patient pools, so these incentives help make the development economically viable. The other policies don’t focus on rare-disease drug development or tax-based encouragements: switching policy isn’t a recognized framework for this purpose, fast track speeds up review without providing tax benefits, and OTC policy deals with over-the-counter status rather than development incentives. Therefore, the policy described is the Orphan Drug Law.